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Background: ‘Lupus brain fog’ is a phenomenon of cognitive function decline in SLE patients. 
Premature immunosenescence in SLE was presumed to play a significant role in the 
mechanism of cognitive dysfunction. 
Aim: To prove the correlation between the terminally-differentiated CD4+CD57+, CD8+CD57+, 
CD4+KLRG1+, and CD8+KLRG1+ T-Cells & serum MMP-9 levels with cognitive dysfunction in SLE 
patients. 
Methods: There were53 women SLE were conducted to perform MMSE and MoCA-Ina tests to 
evaluate cognitive function. Immunosenescence was observed by measuring the terminally-
differentiated CD4+CD57+, CD8+CD57+, CD4+KLRG1+, and CD8+KLRG1+ T-Cells, which were 
measured by flowcytometry. In addition, MMP-9, an enzyme produced by terminally-
differentiated T-Cells, was measured using ELISA. 
Results: SLE patients with cognitive dysfunction based on MMSE and MoCA-Ina test had higher 
percentage of CD4+CD57+, CD8+CD57+, CD4+KLRG1+, CD8+KLRG1+ T-Cells and serum MMP-9 level 
compared to patients with normal cognitive function. CD4+CD57+, CD8+CD57+, CD4+KLRG1+, 
CD8+KLRG1+ T-Cells percentage and serum MMP-9 level showed negative correlation with both 
MMSE scores (r = -0.286; r = -0.447; r = -0.279; r = -0.537; r = -0,411) and MoCA-Ina scores (r = -
0.454; r = -0.539; r = -0.435; r = -0.535; r = -0.648). Meanwhile, percentage of CD4+CD57+, 
CD8+CD57+, CD4+KLRG1+ and CD8+KLRG1+ T-Cells showed positive correlation with serum MMP-
9 level (r = 0.292; r = 0.414; r = 0.449; r = 0.374). 
Conclusion:  Expansion of CD4+CD57+, CD8+C57+,CD4+KLRG1+, CD8+KLRG1+ terminally 
differentiated T-Cells& increase of serum MMP-9 level are correlated with cognitive dysfunction 
in SLE patients. 
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I N T R O D U C T I O N  
The clinical manifestation of 
degeneration in Systemic Lupus Erythematosus 
(SLE) showed a similar profile as in the elderly 
population, including a cognitive function 
decline.(1–3) The cognitive dysfunction in SLE, 
‘lupus brain fog’, is reported in 20-80% of SLE 
patients. Cognitive dysfunction is correlated 
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with decreased quality of life, social 
participation, and increased stress, anxiety, 
and depression. This condition can reduce 
patient compliance in carrying out treatment 
programs, thus worsening the prognosis of SLE 
disease. In addition, cognitive dysfunction in 
SLE will lead to higher medical costs. Therefore, 
early detection and appropriate treatment of 
cognitive dysfunction are challenges in holistic 
SLE management.(4,6–8) Although the case rate is 
high, the specific management of cognitive 
dysfunction in SLE is still minimal due to limited 
studies that can clearly explain the causes and 
underlying pathophysiological mechanisms.(3–5) 
Immunosenescence is a phenomenon 
of the aging process that occurs in the immune 
system. Immunosenescence in adaptive 
immunity affects T lymphocytes both CD4+ and 
CD8+. Under these conditions, cells did not 
express costimulatory molecules such as CD27 
and CD28, and expressed markers such as killer 
cell lectin-like receptor sub family G (KLRG1) 
and CD57. Therefore, KLRG1 and CD57 are 
considered markers of terminal differentiation 
or cellular senescence. These terminally 
differentiated cells have an inflammatory 
phenotype that causes an increase in the 
formation of cytokines and pro-inflammatory 
enzymes such as IL-6, TNFα, PGE2, and MMP-9. 
This inflammatory state is called inflammaging, 
which is a characteristic feature of 
immunosenescence.(9) Several studies have 
demonstrated a neuro-immunological 
relationship and the role of immunosenescence 
in inducing accelerated brain aging, memory 
loss, and other neuro-degenerative 
manifestations.(10) In SLE patients, early 
immunosenescence is a key mechanism in the 
neuropath logical processes underlying 
cognitive dysfunction. Several studies have 
shown an inverse correlation between 
increased pro-inflammatory cytokines in the 
peripheral circulation and memory 
performance in SLE patients.(4,11,12) Similarly, 
MMP-9 is well known to cause damage to the 
blood-brain barrier and mediate cognitive 
dysfunction.(4) 
This study determines the relationship 
among the expansion of CD4+CD57+, 
CD8+C57+, CD4+KLRG1+, CD8+KLRG1+ 
terminally differentiated T-Cells and MMP-
9with cognitive dysfunction in SLE patients. 
M E T H O D S 
Design and Subjects of Study 
The subjects of this study were 53 
female patients aged 16-45 years who met the 
SLE classification criteria based on the 2012 
Systemic Lupus International Collaborating 
Clinics (SLIML) and an active SLEDAI score >3. 
Severe infection, pregnancy or lactation, 
impaired consciousness, or a history of 
cognitive dysfunction before SLE diagnosis 
were exclusion criteria for study subjects.  All 
subjects were active SLE patients at the 
Rheumatology polyclinic, Department of 
Internal Medicine, RSUD Dr.  Saiful Anwar 
Malang. All subjects in this study had signed an 
informed consent form, and all of the study 
protocols were approved by the Ethics 
Commission of RSUD Dr.  Saiful Anwar Malang 
No. 400/120/K.3/302/2017. 
Basic Data Collection and Blood Collection 
Data were obtained from interviews 
and direct examination of patients, including 
demographic data, clinical data (onset of 
disease, history of clinical manifestations since 
first diagnosed, current complaints, and 
medical history). In addition, a total of 10 ml of 
venous blood was taken in a tube with heparin 
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for PBMC isolation, a plain tube for blood serum 
chemistry (C-reactive protein (CRP), antibody 
anti-dsDNA, levels of complement C3 and C4), 
and an EDTA tube for a complete blood count.   
Examination of Cognitive Function 
Cognitive function was assessed with 
the Mini-Mental State Examination (MMSE) and 
Montreal Cognitive Assessment Indonesian 
version (MoCA-Ina) that previous studies have 
validated. The work of the two tests was carried 
out independently by the study subjects with 
direct direction and supervision from the study 
team. It was declared cognitive dysfunction if 
the MMSE score <24 or MoCA-Ina score <26 or 
both.(13,14) 
Isolation of Peripheral Blood Mononuclear 
Cells (PBMC) 
PBMCs were separated from whole 
blood by centrifugation of 1600 g and using 
Ficoll gradient Lymphoprep (Stemcell 
Technology Catalog no.07801).  Then, the 
PBMCs were washed and divided into aliquots 
for immunopheno typing assays.  
Measurement of the percentage of 
CD4+CD57+, CD8+CD57+, CD4+KLRG1+, and 
CD8+KLRG1+ T-Cells 
PBMCs for phenotyping were blocked 
by 2% mouse serum before being labeled with 
three panels of the fluorochrome-conjugated 
(FITC) monoclonal antibodies to the surface 
markers studied, namely CD3, CD4 or CD8, and 
CD57 or KLRG1: anti-human CD3 antibody 
(Biolegend; cat number 300405), PerCP anti-
human CD4 antibody (Biolegend; cat number 
300527), PerCP anti-human CD8 antibody 
(Biolegend; cat number 344707), PE anti-
human CD57 antibody (Biolegend; cat number 
830795) and PE anti-human KLRG1 (Biolegend; 
cat number 367704). Cells were fixed with 
paraformaldehyde.  Flowcytometry was 
performed using BD Cell Quest (BD FACS 
Calibur) software.  Measurements based on 
10,000 cells, and the results were obtained as a 
percentage (%). 
Measurement of Serum MMP-9 Enzyme 
Levels  
MMP-9 enzyme levels were measured 
from serum, using the ELISA method by 
Biolegend kit (cat number 444907).  ELISA 
measurements were performed according to 
the manufacturer's protocol. 
Statistical Analysis 
Overall statistical tests & table 
generation were performed using IBM SPSS for 
Windows version 23.0. Comparisons among 
groups were analyzed using an independent 
(unpaired) parametric T-test, while non-
parametric data were analyzed using the Mann-
Whitney test. Comparison between categorical 
variables were using chi-square test. The 
correlation between T-Cells and serum MMP-9 
levels with cognitive dysfunction based on 
MMSE and MoCA-Ina scores in SLE patients was 
assessed by Pearson's test for parametric data 
and Spearman's test for non-parametric data. 
The statistical test is significant if the p-value 
<0.05. In addition, parametric data is presented 
in the form of mean ± SD, while non-parametric 
data is presented in the median (25-75th 
percentile). 
R E S U L T S 
Characteristics of Study Subjects 
A total of 53 subjects with SLE patients 
aged 28.3 ± 6.5 years old, with the onset of 
clinical symptoms related to SLE were 24 ± 5.8 
years.  Neuropsychiatric manifestations of SLE 
were found in 6 (11.3%) study subjects.  
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Cognitive function examinations were 
performed using different instruments, namely 
MMSE and MoCA-Ina, which showed median 
values of 24 (20-26) and 26 (24-28), respectively.  
The primary characteristics of the study 
subjects are presented in Table 1. 
From 53 study subjects, 24 patients 
(45.3%) LES with cognitive dysfunction were 
found based on the results of the MMSE test, 
and 23 patients (43.4%) based on the results of 
the MoCA-Ina test.  The number of patients with 
a history of neuropsychiatric SLE events was 
significantly higher in the subjects of SLE 
patients with cognitive dysfunction based on 
the results of the MMSE test compared to the 
group without cognitive dysfunction (20.8% vs. 
3.4%, p = 0.047). However, duration, medication 
history, educational history, socioeconomic 
background, CRP levels, increased anti-dsDNA 
and decreased complement did not provide 
significant differences between the two groups, 
based on the results of the MMSE and MoCA-Ina 
(Table 2 and 3).  
Table 1. Baseline Characteristics of Study Subjects 
Variable Mean/Median/ n (%) 
Age (year) 28.3 ± 6.5 
Onset (year) 24.0 ± 5.8 
Duration (month) 24 (24-78) 
ClinicalManifestation  
• Neuropsychiatry SLE 6 (11.3) 
• Arthritics 14 (26.4) 
• Myositis 1 (1.9) 
• Mucocutaneous manifestation 23 (43.4) 
• Vasculitis 13 (24.5) 
• Nephritis  25 (47.2) 
• Serositis 10 (18.9) 
• Thrombocytopenia 4 (7.5) 
• Leukopenia 15 (28.3) 
Cognitive Test  
• MMSE Score 24 (20-26) 
• MoCA-Ina Score 26 (24-28) 
Education Background  
• ≤ Upper secondary education 35 (66.0) 
• ≥ Undergraduate 18 (34) 
Socioeconomics  
• Working 14 (26.4) 
• Paid <1.500.000/month (IDR) 47 (88.7) 
• Paid ≥1.500.000/month (IDR) 6 (11.3) 
Therapy  
• steroid  48 (90.5) 
• Chloroquine 13 (81.1) 
• Cyclophosphamide 3 (5.6) 
• Azathioprine 21 (39.6) 
• Mycophenolate mofetil  9 (16.9) 
CRP (mg/dL) 0.19 (0.09-0.80) 
Anti-dsDNA (IU/mL) 85.10 (38.60–198.40) 
CD4/CD8 Ratio 0.8 (0.6-1.2) 
IRP positive 33 (62.2) 
SLEDAI Score 6 (4-13) 
MMSE: Mini Mental State Evaluation; CRP: C Reactive Protein; SLE: 
Systemic Lupus Erythematosus; IDR: Indonesian Rupiah; IRP:  Immune 
Risk Profile
 
Table 2. Differences in Characteristics of Study Subjects based on MMSE Test Results 
Variable SLE Patients with Cognitive Dysfunction (n=24) SLE Patients without Cognitive Dysfunction (n=29) p 
Duration (month) 33 (21.7-84) 24 (24-66) 0.971 
NP SLE history, n (%) 5 (20.8) 1 (3.4) 0.047** 
Treatment, n (%)    
• Steroid 21 (87.5) 27 (93.1) 0.487 
• Chloroquine 20 (83.3) 23 (79.3) 0.709 
• Cyclophosphamide 1 (4.2) 2 (6.89) 0.669 
• Azathioprine 8 (33.3) 13 (44.8) 0.394 
• Mycophenolate mofetil 5 (20.8) 4 (13.7) 0.497 
Education Background, n (%)    
• ≤ Upper secondary education 17 (70.8) 18 (62.1) 0.502 
• ≥ Undergraduate 7 (29.2) 11 (37.9)  
Socioeconomics, n (%)    
• Paid < 1.500.000/month (IDR) 22 (91.7) 25 (86.3) 0.532 
• Paid ≥ 1.500.000/month (IDR) 2 (8.3) 4 (13.7)  
CRP (mg/L) 0.25 (0.11-1.35) 0.12 (0.08–0.7) 0.122 
Increasing anti-dsDNA, n (%) 16 (66.7) 22 (75.9) 0.459 
Decreasing complement, n (%) 0 (0.0) 0(0.0) n/a 
*) Cognitive dysfunction was based on MMSE scores < 24; **) The differences between the two groups were statistically significant                 (p < 0.05); 
MMSE: Mini Mental State Evaluation; CRP: C Reactive Protein; SLE: Systemic Lupus Erythematosus; IDR: Indonesian Rupiah
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Table 3. Differences in Characteristics of Study Subjects based on MoCA-Ina Test Results 
Variable 
SLE Patients with Cognitive 
Dysfunction (n=24) 
SLE Patients without Cognitive 
Dysfunction (n=29) 
p 
Duration (month) 30 (24-84) 24 (22-5.60) 0.676 
NP SLE history, n (%) 4 (17.3) 2 (6.7) 0.222 
Treatment, n (%)    
• Steroid 20 (87.0) 28 (93.3) 0.431 
• Chloroquine 18 (78.3) 25 (83.3) 0.640 
• Cyclophosphamide 0 (0.0) 3 (10.0) 0.118 
• Aazathioprine 6 (26.1) 15 (50.0) 0.078 
• Mycophenolate mofetil 6 (26.1) 3 (10.0) 0.122 
Education Background, n (%) 
• ≤ Upper secondary education 17 (73.9) 18 (60.0) 0.289 
• ≥ Undergraduate 6 (26.1) 12 (40.0)  
Socioeconomics, n (%) 
• Paid < 1.500.000/ month (IDR) 21 (91.3) 26 (86.7) 0.597 
• Paid ≥ 1.500.000/ month (IDR) 2 (8.7) 4 (13.3)  
CRP (mg/L) 0.20 (0.09-0.80) 0.16 (0.09-0.82) 0.706 
Increasing anti-dsDNA, n (%) 18 (78.3) 20 (66.7) 0.353 
Decreasing complement, n (%) 0 (0.0) 0 (0.0) n/a 
*) Cognitive dysfunction was based on MMSE scores < 24; *) Cognitive dysfunction based on MoCA-Ina scores < 2; IDR: Indonesian Rupiah
Comparison of Percentage of CD4+CD57+, 
CD8+CD57+, CD4+KLRG1+, CD8+KLRG1+ T-Cells, 
and Serum MMP-9 Levels by Functional 
Cognitive Status of SLE Patients 
Terminally-differentiated T-Cells were 
represented with CD4, CD8 T-Cells expressing 
CD57, and CD4 T-Cells expressing KLRG1.  The 
percentage of CD4+CD57+ T-Cells was found to 
be significantly higher in the SLE patient group 
with cognitive dysfunction when compared to 
the group without cognitive dysfunction, as 
assessed by the MMSE test [1.99% (0.73-3.25) 
vs. 0.86% (0.75-1.411); p = 0.006] and MoCA-Ina 
[2% (0.78-3.32) vs.  0.8% (0.48-1.33); p = 0.005]. 
Similar results were also obtained for the 
percentage of CD8+CD57+ T-Cells, which were 
significantly higher in the SLE patient group 
with cognitive dysfunction based on the results 
of the MMSE test (13.44 ± 6.12% vs. 8.12 ± 6.26%; 
p = 0.000) and MoCA-Ina (14.41 ± 6.41% vs.  7.55 
± 5.29%; p = 0.000) when compared with the 
group without cognitive dysfunction.  
The percentage of CD4+KLRG1+ T-Cells 
was also found to be significantly higher in the 
SLE patient group with cognitive dysfunction 
compared to the group without cognitive 
dysfunction, as assessed by the MMSE test 
[4.38% (2.28-5.65) vs.  1.67% (1-3.24); p = 0.003] 
and MoCA-Ina [4.77% (2.68-5.68) vs.  1.57% 
(1.07-3.15); p = 0.004]. Similar results were also 
obtained for the percentage of CD8+KLRG1+ T-
Cells, which were significantly higher in the SLE 
patient group with cognitive dysfunction based 
on the results of the MMSE test (15.82 ± 6.93% 
vs. 9.37 ± 5.71%; p = 0.000) and MoCA-Ina (16.58 
± 6.61% vs. 9.37 ± 5.71%; p = 0.000) and MoCA-
Ina (16.58 ± 6.61% vs. 9.01 ± 5.42%; p = 0.000) 
compared with the group without cognitive 
dysfunction.   
The MMP-9 enzyme was another 
variable observed in this study. MMP-9 is a 
terminally-differentiated T-Cells product and is 
expected to mediate cognitive dysfunction in 
SLE patients. Serum MMP-9 enzyme levels in 
SLE patients with cognitive dysfunction were 
found to be significantly higher than in SLE 
patients without cognitive dysfunction, based 
on the results of the MMSE test [2669.75 ± 
953.46 ng/ml vs. 1861.58 ± 628.73 ng/ml, 
p=0.000] and MoCA-Ina [2888.78 ± 769.33 ng/ml 
vs. 1720.59 ± 580.34 ng/ml, p=0.000]. The 
percentage comparison of CD4+CD57+, 
CD8+CD57+, CD4+KLRG1+, CD8+KLRG1+ T-Cells, 
and serum levels of MMP-9among groups of 
study subjects are presented in Figure 1. 
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Figure 1. The percentage comparison of CD4+CD57+T-
Cells(A) CD8+CD57+T-Cells,(B) CD4+KLRG1+T-Cells, (C) 
CD8+KLRG1+ T-Cells (D) Serum levels of MMP-9 (E) in SLE 
patients with and without Cognitive Dysfunction (data 
presented in the median form in Figures 2.A and 2 .C and in 
the form of the mean in Figures 2.B,2.D and 2.E) 
Correlation among the percentage of 
CD4+CD57+, CD8+CD57+, CD4+KLRG1+, 
CD8+KLRG1+, and serum levels of MMP-9with 
Cognitive Function in SLE Patients 
The relationship between 
immunosenescence in SLE patients and the 
occurrence of cognitive decline was assessed 
by correlation test between the percentage of 
CD4+CD57+, CD8+CD57+, CD4+KLRG1+ and 
CD8+KLRG1+ T-Cells with MMSE and MoCA-Ina 
scores (Figures 2A, 2B, 2C & 2D). The results of 
the Spearman test showed that the percentage 
of CD4+CD57+ T-Cells had a weak negative 
correlation with the MMSE score (r = -0.286; p = 
0.038) and a moderate negative correlation 
with the MoCA-Ina score (r = -0.454; p = 0.001).  A 
moderate negative correlation was also found 
between the percentage of CD8+CD57+ T-Cells 
and the MMSE score (r = -0.447; p = 0.001), while 
for the MoCA-Ina score, this variable showed a 
strong negative correlation (r = -0.539; p = 0.000) 
From the test, it was also found that the 
percentage of CD4+KLRG1+ T-Cells had a weak 
negative correlation with the MMSE score (r= -
0.279; p=0.043) and a moderate negative 
correlation with the MoCA-Ina score (r= -0.435; 
p=0.001).  A strong negative correlation was 
found among the percentage of CD8+KLRG1+ T-
Cells with the MMSE score (r= -0.537; p=0.000), 
and with the MoCA-Ina score (r= -0.535; 
p=0.000). 
The relationship between serum levels 
of MMP-9, a product produced by terminally-
differentiated T-Cells, and cognitive function 
also showed a significant negative correlation 
(Figure 2E).  The results of statistical analysis 
showed a moderate negative correlation 
between serum levels MMP-9 and the MMSE 
score (r = -0.411; p = 0.002) and a strong 
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negative correlation with the MoCA-Ina score (r 
= -0.648; p = 0.000).     
Correlation among Percentage of CD4+CD57+, 
CD8+CD57+, CD4+KLRG1+, CD8+KLRG1+T-Cells, 
and Serum MMP-9 Levels 
MMP-9 is a terminally-differentiated T-
Cells product and is suspected of mediating 
cognitive dysfunction in SLE patients through 
the immunosenescence pathway. The 
correlation test among the percentage of 
CD4+CD57+, CD8+CD57+, CD4+KLRG1+, 
CD8+KLRG1+ T-Cells, and serum MMP-9 levels 
was carried out to assess the correlation and 
clarify the position of each of these variables in 
Pathophysiological pathway mechanisms of 
cognitive dysfunction in SLE patients. 
Statistical analysis results showed that the 
percentage of CD4+CD57+T-Cells had a weak 
positive correlation of MMP-9 serum (r = 0.292; 
p = 0.034) and that CD8+CD57+ T-Cells had a 
moderately positive correlation of serum MMP-
9 (r = 0.414; p = 0.002) as shown in Figure 2F. 
Whereas statistical analysis results showed that 
the percentage of CD4+KLRG1+ and CD8+KLRG1- 
T-Cells had a moderately positive correlation 
with serum MMP-9 levels (r = 0.449; p = 0.001 & r 
= 0.374; p = 0.006) as shown in Figure 2G. 
 
Figure 2. Correlation between MMSE and MoCA-Ina 
scores with The Percentage of CD4 +CD57+ T-Cells (A), 
CD8+CD57+ T Cell (B), CD4+KLRG1+ T Cell (C), CD8+KLRG1+ 
T-Cells (D) Serum MMP-9 Levels (E) in SLE Patients; and 
the correlation among serum MMP-9 levels with the 
percentage of CD4+CD57+, CD8+CD57+ T-Cells (F) and the 
percentage of CD4+KLRG1+, CD8+KLRG1+ T-Cells(G) 
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D I S C U S S I O N  
Our study shows that SLE patients with 
Cognitive dysfunction show a different 
manifestation of peripheral immunity from 
normal cognitive SLE patients.  Patients with 
cognitive dysfunction showed a significantly 
higher percentage of CD4+CD57+T-Cells and a 
negative correlation between the percentage of 
CD4+CD57+T-Cells and cognitive function.  
Expression of CD57 on CD4 T-Cells causes 
characteristic changes that make these cells 
classified as cytotoxic 1 helper T-Cells.  These 
cells showed the ability of cytolytic cells and 
correlated with the expression of cytolytic 
granules, granzyme B, and perforin, which are 
cytotoxic molecules and induce tissue damage, 
both of which are physiologically only 
possessed by NK cells and cytotoxic CD8+ 
cells.15 These cells are the predominant 
component involved in neurodegenerative and 
neuro-inflammatory diseases through pro-
inflammatory cytokine pathways and direct 
effects of cytotoxicity on neuronal cells.(10) 
Another study by Magistrelli et al. 
revealed that the number of CD4 T-Cells present 
in peripheral blood circulation had an inverse 
relationship with cognitive function in patients 
with Parkinson's disease, assessed using the 
Adden brooke Cognitive Examination (ACE-
R).(16) SLE is a chronic inflammatory disease in 
which the peripheral immune profile also 
shows pro-inflammatory properties, thus giving 
a similar manifestation to Parkinson's disease.  
In this study, CD8T+CD57+T-Cells were 
also significantly higher in SLE patients with 
cognitive dysfunction than the normal 
cognitive group.  Recent studies have shown 
that the expansion of CD8+CD57+T-Cells is 
associated with the phenomenon of 
immunosenescence, and the presence of these 
cells is associated with inflammatory activity 
due to the ability to secrete pro-inflammatory 
cytokines, cytotoxic molecules such as 
granzyme and perforin, proliferate and persist 
for a longer period due to resistance to 
apoptosis, in which also known as NK-like CD8+ 
Effector Memory T Cell.(17,18) 
This study also showed that the 
percentage of CD4+KLRG1+T-Cells was 
significantly higher in SLE patients with 
cognitive dysfunction and that there was a 
negative correlation between the percentage of 
CD4+KLRG1+T-Cells and cognitive function.  This 
is consistent with the results of a study by 
Pellicano et al, where KLRG1 on CD4 T-Cells 
were also higher in patients with Alzheimer's 
disease, where this disease is characterized by 
decreased cognitive function.(19) 
Several studies found that KLRG1 
expression on CD4 T-Cells correlated with an 
increase in interferon-gamma and cytotoxic 
responses.(20–22) KLRG1 also induces 
phosphorylation of N-cadherin in which 
affecting down regulation of the N-cadherin. N 
(neuronal)-cadherin found in brain tissue 
functions to maintain tissue integrity by being a 
liaison between cells. Therefore, if there is a 
down regulation due to KLRG1, it will cause the 
relationship between these cells to be 
disrupted and not optimally carry out their 
functions.(23,24) 
Whereas, KLRG1 expression on CD8 T-
Cells, a study conducted by Novelli found that 
KLRG1 expression increased with age, with 
more than 90% of its expression on CD8 T-Cells 
in individuals over 65 years of age.(25) From a 
study conducted by Wheeler, it was found that 
CD8+KLRG1 T-Cells were increased in patients 
with age-related cognitive dysfunction.(26) 
The decline in cognitive function is 
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associated with the expansion of 
CD4+CD57+/KLRG1+ T-Cells and 
CD8+CD57+/KLRG1+ T-Cells related to the 
migration of these cells into brain tissue. It is 
thought that in inflammatory conditions such 
as aging or autoimmune disease, peripheral T-
Cells can cross the brain barrier and induce 
neuronal damage.  This allegation is supported 
by Gamechu and Bentivoglio study that found 
that the T-Cells in peripheral circulation can 
pass through the blood-brain barrier in patients 
with normal aging. Thus, the blood-brain 
barrier's structural and functional disruption 
may occur in normal aging associated with a 
pro-inflammatory phenotype in old age. 
Leukocyte transmigration, which involves 
many steps, occurs primarily in postcapillary 
venules and appears to involve paracellular 
routes and transcellular diapedesis. This cell 
migration is primarily controlled by the 
expression of adhesion molecules, chemokines, 
and their receptors. T-Cells that have crossed 
the barrier will then activate endothelial cells 
by releasing cytokines, which then induce or 
increase the expression of cell adhesion 
molecules.(27) This mechanism accelerates the 
inflammatory cascade many-fold. The 
migration of T-Cells into the brain is also 
facilitated by chemokines secreted by reactive 
astrocytes, including monocyte chemotactic 
protein (MCP)-1 and macrophage inflammatory 
protein-1 (MIP)-1α. On the other hand, the 
matrix metalloproteinase (MMP), secreted by 
activated T-Cells and macrophages, can 
destroy the extracellular matrix components as 
an effector inflammatory response after the 
migration of T-Cells.(28) The changing 
phenotype of senescent T-Cells, cytotoxic and 
pro-inflammatory, allegedly underlie neuro 
inflammation and induces neuronal damage 
through a mechanism commonly referred to as 
inflammaging.(1,10,29) Moreover, the study by 
Kadowaki et al. found that when KLRG1 binds to 
its ligand, N-cadherin on neurons, it causes 
down regulation of the N-cadherin.(30) 
MMP is a molecule that mediates the 
migration of peripheral T-Cells to the brain 
parenchyma, with its role in disrupting tight 
junctions’ blood-brain barrier.  Our study also 
found that serum MMP-9 levels were 
significantly higher in SLE patients with 
cognitive dysfunction, compared to the normal 
cognitive group. The study conducted by 
Ianetta et al. explained that MMP-9 levels were 
correlated with lesions on MRI and multiple 
sclerosis disease activity.  The same study also 
showed an increase in serum MMP-9 levels that 
correlated with the expansion of senescent CD4 
and CD8 T-Cells.  MMP-9 also plays a role in 
neuronal damage by demyelinating neuronal 
axons and causing cell death by excitotoxic 
mechanisms.(31–33) 
C O N C L U S I O N 
Based on the results of this study 
coupled with data from previous studies, it can 
be concluded that immunosenescence has an 
important role in the pathogenesis of cognitive 
dysfunction in SLE patients. The expansion of 
terminally differentiated effect CD4+CD57+, 
CD8+CD57+, CD4+KLRG1+, and CD8+KLRG1+ T-
Cells correlates with cognitive dysfunction in 
SLE patients, both through their direct 
cytotoxicity potential and through their 
intermediary increased production of the 
enzymeMMP-9. Further studies also need to be 
conducted to assess the presence and 
correlation of CD4+CD57+, CD8+CD57+, 
CD4+KLRG1+, CD8+KLRG1+, and MMP-9 in 
cerebrospinal fluid with cognitive function in 
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order to clearly describe the involvement in 
causing cognitive dysfunction in SLE patients.  
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